Credit Suisse Group reaffirmed their hold rating on shares of Henry Schein, Inc. (NASDAQ:HSIC) in a research note issued to investors on Thursday, July 13th. They currently have a $160.00 price target on the stock.
HSIC has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Henry Schein from a hold rating to a buy rating and set a $204.00 price target for the company in a research report on Thursday, May 25th. Piper Jaffray Companies began coverage on shares of Henry Schein in a research note on Monday, June 12th. They issued a neutral rating and a $200.00 price target for the company. Stifel Nicolaus lifted their price target on shares of Henry Schein from $174.00 to $178.00 and gave the stock a hold rating in a research note on Wednesday, May 10th. Craig Hallum began coverage on shares of Henry Schein in a report on Tuesday, April 11th. They set a hold rating on the stock. Finally, Deutsche Bank AG began coverage on shares of Henry Schein in a report on Wednesday, March 15th. They set a hold rating and a $174.00 price objective on the stock. One analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company’s stock. Henry Schein currently has an average rating of Hold and an average target price of $185.56.
Henry Schein (HSIC) traded up 1.95% during mid-day trading on Thursday, reaching $170.58. 628,242 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $181.94 and its 200 day moving average price is $175.01. Henry Schein has a one year low of $146.23 and a one year high of $186.99. The firm has a market cap of $13.49 billion, a price-to-earnings ratio of 24.93 and a beta of 1.09.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period last year, the business earned $1.64 earnings per share. Henry Schein’s revenue was up 6.4% compared to the same quarter last year. On average, equities analysts forecast that Henry Schein will post $7.28 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Henry Schein, Inc. (HSIC) Earns Hold Rating from Credit Suisse Group” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/11/henry-schein-inc-hsic-stock-rating-reaffirmed-by-credit-suisse-group-updated-updated-updated.html.
A number of hedge funds have recently bought and sold shares of the company. SpiderRock Advisors LLC acquired a new stake in Henry Schein during the first quarter worth about $102,000. Lee Financial Co bought a new position in Henry Schein during the second quarter worth $161,000. Westside Investment Management Inc. bought a new position in Henry Schein during the first quarter worth $168,000. JNBA Financial Advisors bought a new position in Henry Schein during the first quarter worth $170,000. Finally, Acrospire Investment Management LLC boosted its position in Henry Schein by 150.0% in the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock worth $183,000 after buying an additional 600 shares in the last quarter. 90.87% of the stock is owned by hedge funds and other institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.